Literature DB >> 8408645

Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

M Wetzler1, M Talpaz, R A Van Etten, C Hirsh-Ginsberg, M Beran, R Kurzrock.   

Abstract

We used specific antisera and immunohistochemical methods to investigate the subcellular localization and expression of Bcr, Abl, and Bcr-Abl proteins in leukemic cell lines and in fresh human leukemic and normal samples at various stages of myeloid differentiation. Earlier studies of the subcellular localization of transfected murine type IV c-Abl protein in fibroblasts have shown that this molecule resides largely in the nucleus, whereas transforming deletion variants are localized exclusively in the cytoplasm. Here, we demonstrate that the murine type IV c-Abl protein is also found in the nucleus when overexpressed in a mouse hematopoietic cell line. However, in both normal and leukemic human hematopoietic cells, c-Abl is discerned predominantly in the cytoplasm, with nuclear staining present, albeit at a lower level. In contrast, normal endogenous Bcr protein, as well as the aberrant p210BCR-ABL and p190BCR-ABL proteins consistently localize to the cytoplasm in both cell lines and fresh cells. The results with p210BCR-ABL were confirmed in a unique Ph1-positive chronic myelogenous leukemia (CML) cell line, KBM5, which lacks the normal chromosome 9 and hence the normal c-Abl product. Because the p210BCR-ABL protein appears cytoplasmic in both chronic phase and blast crisis CML cells, as does the p190BCR-ABL in Ph1-positive acute leukemia, a change in subcellular location of Bcr-Abl proteins between cytoplasm and nucleus cannot explain the different spectrum of leukemias associated with p210 and p190, nor the transition from the chronic to the acute leukemia phenotype seen in CML. Further analysis of fresh CML and normal hematopoietic bone marrow cells reveals that p210BCR-ABL, as well as the normal Bcr and Abl proteins, are expressed primarily in the early stages of myeloid maturation, and that levels of expression are reduced significantly as the cells mature to polymorphonuclear leukocytes. Similarly, a decrease in Bcr and Abl levels occurs in HL-60 cells induced by DMSO to undergo granulocytic differentiation. The action of p210BCR-ABL and its normal counterparts may, therefore, take place during the earlier stages of myeloid development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408645      PMCID: PMC288359          DOI: 10.1172/JCI116786

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Assay formats involving acridinium-ester-labeled DNA probes.

Authors:  L J Arnold; P W Hammond; W A Wiese; N C Nelson
Journal:  Clin Chem       Date:  1989-08       Impact factor: 8.327

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  c-abl has a sequence-specific enhancer binding activity.

Authors:  R Dikstein; D Heffetz; Y Ben-Neriah; Y Shaul
Journal:  Cell       Date:  1992-05-29       Impact factor: 41.582

4.  The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization.

Authors:  R A Van Etten; P Jackson; D Baltimore
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

5.  A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro.

Authors:  A M Gewirtz; B Calabretta
Journal:  Science       Date:  1988-12-02       Impact factor: 47.728

6.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

7.  Retrovirus sequences in a leukemic gibbon and its contact: evidence for partial provirus in the nonleukemic gibbon.

Authors:  F Wong-Staal; M S Reitz; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

8.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.

Authors:  P Jackson; D Baltimore
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  44 in total

1.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

4.  Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function.

Authors:  R Bhatia; E A Wayner; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

Review 5.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

6.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

7.  Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha.

Authors:  R Bhatia; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

8.  Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis.

Authors:  Celia Garcia-Prieto; Kausar Begam Riaz Ahmed; Zhao Chen; Yan Zhou; Naima Hammoudi; Ying Kang; Changgang Lou; Yan Mei; Zhendong Jin; Peng Huang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

9.  Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

Authors:  H Zhang; D Trachootham; W Lu; J Carew; F J Giles; M J Keating; R B Arlinghaus; P Huang
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

10.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.